Technical Analysis for AMAG - AMAG Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 8.045 -2.43% -0.20
AMAG closed down 2.43 percent on Thursday, July 2, 2020, on 81 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical AMAG trend table...

Date Alert Name Type % Chg
MACD Bullish Centerline Cross Bullish 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Crossed Above 20 DMA Bullish -2.43%
Crossed Above 50 DMA Bullish -2.43%
Wide Bands Range Expansion -2.43%
Up 3 Days in a Row Strength -2.43%
MACD Bullish Signal Line Cross Bullish 5.16%
Wide Bands Range Expansion 5.16%
Inside Day Range Contraction 6.77%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The company's principal product includes Feraheme (ferumoxytol) injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company also markets Feraheme in Canada, the European Union, and Switzerland. In addition, its development projects comprise Feraheme for patients with IDA regardless of the underlying cause, which has completed Phase III clinical program. The company sells Feraheme primarily to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as a therapeutic agent in China for an initial indication for the treatment of IDA in patients with CKD and an option to expand into additional therapeutic indications. The company was founded in 1981 and is headquartered in Lexington, Massachusetts.
Biopharmaceutical Health Medication Chronic Kidney Disease European Union

Is AMAG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.53
52 Week Low 4.41
Average Volume 571,658
200-Day Moving Average 9.28
50-Day Moving Average 7.85
20-Day Moving Average 7.70
10-Day Moving Average 7.75
Average True Range 0.58
ADX 13.0
+DI 31.08
-DI 22.46
Chandelier Exit (Long, 3 ATRs ) 7.57
Chandelier Exit (Short, 3 ATRs ) 8.37
Upper Bollinger Band 8.97
Lower Bollinger Band 6.44
Percent B (%b) 0.63
BandWidth 32.83
MACD Line 0.02
MACD Signal Line -0.05
MACD Histogram 0.0643
Fundamentals Value
Market Cap 283.89 Million
Num Shares 35.3 Million
EPS -1.30
Price-to-Earnings (P/E) Ratio -6.19
Price-to-Sales 0.90
Price-to-Book 0.57
PEG Ratio 0.30
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.75
Resistance 3 (R3) 8.80 8.63 8.63
Resistance 2 (R2) 8.63 8.45 8.60 8.59
Resistance 1 (R1) 8.34 8.34 8.25 8.28 8.55
Pivot Point 8.16 8.16 8.12 8.13 8.16
Support 1 (S1) 7.87 7.98 7.78 7.81 7.54
Support 2 (S2) 7.69 7.87 7.66 7.50
Support 3 (S3) 7.40 7.69 7.46
Support 4 (S4) 7.34